Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

1. Akero's EFX drug showed a 39% reversal of liver cirrhosis in patients. 2. The treatment outperformed placebo, which had only a 15% reversal rate. 3. CEO highlights EFX's transformational potential for liver disease treatment. 4. Share prices doubled following the positive Phase 2b study results. 5. Ongoing Phase 3 trials may further validate EFX's effectiveness.